Report Company Directory

IMMUNE PHARMACEUTICALS INC

• Immune Pharmaceuticals Files for Chapter 11 Protection by GlobeNewsWire
• Immune Pharmaceuticals Engages Extera Partners to Pursue Bertilimumab Strategic Transaction by GlobeNewsWire
• UPDATE -- Immune Pharmaceuticals Announces Adjournment of Special Meeting of Stockholders by GlobeNewsWire
• Immune Pharmaceuticals and Vector Therapeutics Sign Option Agreement for Worldwide Ceplene® Rights by GlobeNewsWire
• Immune Pharmaceuticals Reschedules Corporate Update Call by GlobeNewsWire
• Immune Pharmaceuticals Schedules Corporate Update Call by GlobeNewsWire
• New Clinical Data Support Bertilimumab Activity in Bullous Pemphigoid by GlobeNewsWire
• Immune Pharmaceuticals Announces Positive Preclinical Results in Asthma by GlobeNewsWire
• Immune Pharmaceuticals Announces $5 Million Financing by GlobeNewsWire
• Immune Pharmaceuticals Provides a Corporate Update by GlobeNewsWire

IMMUNEERING CORP

• Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025 by GlobeNewsWire
• InsiderInsights Weekly Report: October 25, 2025 by InsiderInsights.com
• InsiderInsights Weekly Report: October 18, 2025 by InsiderInsights.com
• InsiderInsights Weekly Report: October 11, 2025 by InsiderInsights.com
• InsiderInsights.com Daily Ratings Report: October 7, 2025 by InsiderInsights.com
• InsiderInsights Weekly Report: October 4, 2025 by InsiderInsights.com
• InsiderInsights.com Daily Ratings Report: October 1, 2025 by InsiderInsights.com
• Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 by GlobeNewsWire
• Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi by GlobeNewsWire
• Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi by GlobeNewsWire

IMMUNEONCIA THERAPEUTICS

IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.

Immunic Inc

• Fast Forward No. 781 by William Blair
• Takeaways From William Blair’s Innovator Series on The Next Frontier in Cardiovascular Risk: Lp(a) by William Blair
• William Blair’s Innovator Series – The Next Frontier in Cardiovascular Risk: Lp(a); November 5, 9:30 a.m.–2:30 p.m. ET by William Blair
• Fast Forward No. 780 by William Blair
• KOL Call to Discuss DTC Market for Obesity: November 13 at 3:00 p.m. ET by William Blair
• William Blair’s Innovator Series: Radiopharmaceuticals – Hosting Virtual Event on November 13-14, 9 a.m. to 1 p.m. ET by William Blair
• William Blair’s Innovator Series – The Next Frontier in Cardiovascular Risk: Lp(a); November 5, 9:30 a.m.–2:30 p.m. ET by William Blair
• Fast Forward No. 779 by William Blair
• Fast Forward No. 778 by William Blair
• ACR 2025 Abstract Highlights and Conference Itinerary by William Blair